AstraZeneca Secures $18.5 Billion Weight-Loss Drug Deal with China's CSPC

AstraZeneca has entered into a broad partnership with the Chinese pharmaceutical company CSPC Pharmaceutical Group to develop a new generation of obesity and diabetes therapies, Reuters reports. The deal, with a potential value of up to $18.5 billion, is among the largest licensing agreements in the sector since the beginning of 2025, according to data from BioPharma Dive.

The collaboration covers up to eight experimental drug candidates, with the initial focus on four weight-reduction therapies. All of these have been developed using artificial intelligence technologies and CSPC’s proprietary platforms, aimed at extended action and less frequent dosing.

Among them is an injectable therapy with a dual mechanism of action, similar to Eli Lilly’s Zepbound, which is expected to enter Phase 1 clinical trials. The other three candidates utilize different mechanisms and, according to AstraZeneca, have the potential to provide longer-lasting benefits for patients with obesity and related metabolic diseases.

The two companies will also collaborate on four additional projects. Under the agreement, AstraZeneca will be able to apply CSPC’s controlled-release technology, which allows for drug administration once a month or at even longer intervals, including for other products within its own portfolio. Outside of China, the British company will hold the primary commercial and development rights for all programs resulting from the partnership.

Under the terms of the contract, CSPC will receive a $1.2 billion upfront payment. Additionally, up to $3.5 billion is earmarked for achieving research and development milestones, as well as up to $13.8 billion tied to the market success of the products, plus future royalties.

AstraZeneca describes CSPC’s technology as potentially transformative for obesity treatment, particularly regarding improved therapy adherence and patient convenience—two of the primary factors for long-term therapeutic success.

The deal was announced against the backdrop of AstraZeneca’s broader strategy for an increased presence in China, following the company’s commitment to invest $15 billion in the country by 2030. It is also part of a growing wave of licensing agreements between Western pharmaceutical companies and Chinese biotech firms, which increasingly offer innovative therapies that build upon existing solutions.

According to BioPharma Dive, over 60 such deals were announced last year, and at least 10 in January of this year alone. In terms of scale, the agreement between AstraZeneca and CSPC surpasses all similar deals since the start of 2025, with its potential value significantly exceeding the partnership previously established between Hengrui Pharma and GSK.